Paris Panayiotopoulos is a Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. He became an Operating Partner working with Clarus in March 2018. Mr. Panayiotopoulos is focused on growth investments in the biopharmaceutical space.
Prior to joining Clarus, Mr. Panayiotopoulos served as President and Chief Executive Officer and a member of the Board of Directors of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a leading rare cancer company, sold to Takeda Pharmaceuticals in February 2017.
In over twenty years in the biopharmaceutical industry, Mr. Panayiotopoulos also served as President of the North American biopharmaceutical business of Merck KgaA (FWB: MRK), President of the Serono Research and Development Institute and President of Merck Serono, Tokyo, Japan. Mr. Panayiotopoulos is on the Board of Advisors of the non-profit Life Science Cares. Prior to joining Merck KgaA, Mr. Panayiotopoulos was at Eli Lilly & Co. (NYSE: LLY).
Mr. Panayiotopoulos holds a combined BS in Chemistry and Management Studies from University College London and a MS from Cranfield Business School in the United Kingdom.